SCHEMBL24434965

SCHEMBL24434965

CC(C)(C)c1csc(NC(=O)c2cccn2Cc2ccccc2Cl)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.50
RAB9A P51151 8/20 0.50
LMNA P02545 6/20 0.50
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
MAP3K14 Q99558 1/20 0.50
NPSR1 Q6W5P4 4/20 0.49
KDM4E B2RXH2 4/20 0.49
HSD17B10 Q99714 3/20 0.49
HTT P42858 3/20 0.49
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
POLB P06746 3/20 0.49
MAPK1 P28482 2/20 0.49
MAPT P10636 4/20 0.48
HPGD P15428 4/20 0.48
ALOX15 P16050 2/20 0.48
TSHR P16473 1/20 0.48
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31466319 1.00 NPC1 (0.50) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL24434560 0.89 SMN1; SMN2 (0.51) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL24435339 0.88 LMNA (0.44) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL24435435 0.88 MEN1 (0.57) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL24434537 0.84 SMN1; SMN2 (0.60) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL31466381 0.78 NPC1 (0.39) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL24435049 0.78 NPC1 (0.39) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL24435129 0.78 SMN1; SMN2 (0.39) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL24434601 0.77 CYP1A2 (0.47) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL24434977 0.76 SMN1; SMN2 (0.49) NPC1RAB9ALMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G NPC1 407/4885RAB9A 222/4885LMNA 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.